Ars Pharmaceuticals Inc (SPRY)

$AQST My guess is that the market makers saw that $SPRY broke its yearlong support with volume and they punished the entire sector.

$AQST $SPRY The best time to plant a tree was 20 years ago. The next best time is today. Join us SPRY brothers and sisters - you are all more than welcome

$SPRY market is over reacting to the down side. Sit tight reversal coming... Earnings will 180 this ship.

$SPRY so glad I bought in today lol. What the hell is happening? Nothing but positive catalysts on the horizon. Someone make me feel better lol

$SPRY okay maybe neffy isn't as friendly of a little guy as I thought

$SPRY Don't know a lot about the company, but i work in the EMS field. We see allergic reactions all the time. This product seems like a no brainer.

$SPRY Current Stock Price: $9.28 Contracts to trade: $10 SPRY Nov 21 2025 Call Entry: $0.75 Exit: $1.26 ROI: 68% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

$AQST $SPRY 50m more and our market cap will be higher than sprys 🥳

$SPRY Lost the 9.5 support

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $SPRY Current Share Price: $9.77 Contracts: $SPRY June 18, 2026 $10 Calls Scale in: $2.49- $3.04 Scale out: $3.87-$4.97 Can Easily Capture: 60% ROI Blended DTE: 238 Days | Join Elites here: https://liquidtheta.com/options

$AQST market makers will let the aqst market cap briefly pass $SPRY. That's about 9.50 for spry and 8 for aqst.

$SPRY Sustained high off-exchange (ATS) trading activity and unusual price behavior between June 30 and September 19, 2025, that appear inconsistent with fair and transparent market dynamics. Summary of Findings (refer to volume table below) Between June 30 – September 19, 2025, weekly off-exchange volume rose from 1.99 million to 3.51 million shares, averaging ≈30% of total trading. During this same period, total market volume increased approximately 2.5×, while the share price declined from $17.50 to $9.79 (−44%). The consistent 25–32% dark-pool share of total trading is abnormally high for a small-cap biotech, suggesting liquidity routing away from lit exchanges and potential impairment of transparent price discovery. Key Market Events and Catalysts Despite multiple major global milestones and value-enhancing developments, SPRY’s share price continued to decline during a period of elevated off-exchange trading: 1) June 2025 – EURneffy® 2 mg launched in Germany by ALK-Abelló, marking the first commercial rollout of ARS Pharmaceuticals’ intranasal epinephrine treatment in Europe. 2)July 18, 2025 – The U.K. formally approved EURneffy® (adrenaline nasal spray) as the first and only needle-free emergency treatment for anaphylaxis, representing a major European regulatory achievement. 3)September 19, 2025 – Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Neffy, ARS Pharmaceuticals’ intranasal epinephrine product, establishing its first regulatory authorization in Asia. 4)September 29, 2025 – The company announced $250 million in non-dilutive funding, materially strengthening its financial position without issuing new equity. 5)October 8, 2025 – The European Patent Office confirmed Neffy’s patent protection through 2039 across more than 30 European countries, securing long-term exclusivity in key markets. Each of these catalysts would typically drive higher investor confidence and support price appreciation. However, the data show increasing total and dark-pool volumes during a continuing price decline — signaling liquidity absorption and muted price discovery. If upcoming November earnings is a beat coupled with XUS approvals (Canada, New Zealand & Australia) all but Australia expected before year end…combined with lower off exchange trading. Consider this an $RKLB rocket ship ready to take off to another atmosphere. Lol. In all seriousness in my opinion only, the recent dip is a blessing for anyone that believes in the next EpiPen first and only needle free alternative Neffy (just launched worldwide ) and hives treatment (currently in under the radar phase two trials)! This could be the next red hot sector similar to $GSAT $ASTS $RKLB $SATS Good luck to all and not financial advice.

@sogenerous $SPRY they have great potential to capture the market. I think one time you posted a comment on this company. https://ars-pharma.com

$KURA $SPRY Great! If you have sold Kura, why TF do you keep posting about it? There’s the door now f off! When you’re finished praising yourself, here’s some truth, so listen up. YOU SOLD EARLY Congratulations 😂

Thanks- not about being right or wrong, just finding the best r/r $KURA $SPRY

@JFais $SPRY In addition the to below catalysts (multiple major global milestones and value-enhancing developments)….Canada, New Zealand and possibly Australia getting approved by year end are a huge de-risk with huuuge upside. *June 2025 – EURneffy® 2 mg launched in Germany by ALK-Abelló, marking the first commercial rollout of ARS Pharmaceuticals’ intranasal epinephrine treatment in Europe. *July 18, 2025 – The U.K. formally approved EURneffy® (adrenaline nasal spray) as the first and only needle-free emergency treatment for anaphylaxis, representing a major European regulatory achievement. *September 19, 2025 – Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Neffy, ARS Pharmaceuticals’ intranasal epinephrine product, establishing its first regulatory authorization in Asia. *September 29, 2025 – The company announced $250 million in non-dilutive funding, materially strengthening its financial position without issuing new equity. * October 8, 2025 – The European Patent Office confirmed Neffy’s patent protection through 2039 across more than 30 European countries, securing long-term exclusivity in key markets. Additionally this commercial was aired during prime time NFL Monday Night Football. I think ARS is doing a heck of a job building brand awareness and recognition on such a big stage! Thinking investors will be pleasantly surprised before year end. All my opinion only and would never want my post to be a decision maker. Do your own research and wishing everyone all the best my friend. https://youtu.be/INqeijbY9Q4

$SPRY- weak on strong day for the sector. Think that even with Neffy scripts jumping in Q3 (peak prescribing season), could sell off to $8.X or so to finish out the year (still work to be done on brand awareness & education efforts)

$AQST a few days or weeks from flipping $SPRY as they deserve for using lawfare to block options for patients

$SPRY $AQST Is that why the fda decided not to have an adcom? They do not need independent experts to evaluate the safety and efficacy of a drug with serious concerns? Have you seen their results? specifically their OASIS study? Do not need to rush because it is second to market? You have no credibility with the stupidity of that comment. You believe coming to market first with an inferior product, will cause the fda with purposely take their time with subsequent filings for the same application? I laugh just writing it. Anaphylm would represent the ONLY non device solution which addresses a huge issue with device administration..Carry rates. Nothing wrong with being bearish or short a stock, but your rationale is sad and piss poor. If you are long SPRY/short AQST, you might want to sit down and do a bit more DD. Of course it is possible that Anaphylm never gets approved and neffy dominates the space. It is also possible you could strike oil digging holes in your backyard